Treatment of vascular occlusions using ultrasonic energy and microbubbles

• US 8,740,835 B2
• Filed: 02/17/2011
• Issued: 06/03/2014
• Est. Priority Date: 02/17/2010
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: EKOS Corporation (Boston Scientific Corporation)
• Inventors: Soltani, Azita, Hansmann, Douglas R.
• Primary Examiner(s): MENDEZ, MANUEL A
• Application Number:
  US13/029,962
• Publication Number:
  US 20110201974A1
• Time in Patent Office: 1,202 Days
• Field of Search: 604/22, 604/93.01
• US Class Current: 604/22
• CPC Class Codes: A61B 17/2202 the ultrasound transducer being inside patient's body at the distal end of the catheter
• CPC Class Codes: A61B 2017/22021 electric leads passing through the catheter
• CPC Class Codes: A61B 2018/00023 closed, i.e. without wound contact by the fluid
• CPC Class Codes: A61B 2018/00648 using more than one sensed parameter
• CPC Class Codes: A61B 2018/00797 measured by multiple temperature sensors
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61N 2007/0039 using microbubbles
• CPC Class Codes: A61N 7/022 intracavitary

Abstract

In one embodiment of the present invention, a method of treating a vascular occlusion located at a treatment site within a patient'"'"'s vasculature comprises positioning an ultrasound catheter at the treatment site. The method further comprises delivering a microbubble-therapeutic compound from the ultrasound catheter to the vascular occlusion during a first treatment phase.

Claims

1. A method of treating a vascular occlusion located at a treatment site within a patient'"'"'s vasculature, the method comprising:

positioning an ultrasound assembly at the treatment site;

delivering a diluted microbubble-therapeutic compound from the ultrasound assembly to the vascular occlusion, wherein the diluted microbubble-therapeutic compound has;

(1) an initial microbubble concentration of less than or equal to approximately 1% by volume of an original microbubble concentration at the deliverance to the ultrasound assembly;

or

(2) an effective microbubble concentration of less than or equal to approximately 0.01% of the original microbubble concentration at deliverance into the vascular occlusion; and

delivering ultrasonic energy from the ultrasound assembly to the vascular occlusion concurrently.

2. The method of claim 1, wherein the dilute microbubble-therapeutic compound comprises biological or synthetic-shelled microbubbles.

3. The method of claim 2, wherein the biological or synthetic-shelled microbubbles are less than or equal to approximately 10 micrometers in diameter.

4. The method of claim 1, wherein the diluted microbubble-therapeutic compound and/or ultrasonic energy are delivered concurrently and continuously.

5. The method of claim 1, wherein the ultrasonic energy has a peak rarefaction acoustic pressure less or equal to approximately 5.0 MPa.

6. A method of treating a vascular occlusion located at a treatment site within a patient'"'"'s vasculature, the method comprising:

passing an ultrasound assembly through the patient'"'"'s vasculature to the treatment site, wherein the ultrasound assembly comprises at least one distal fluid delivery port and at least one ultrasound radiating member;

delivering a microbubble-therapeutic compound at the proximal end of fluid delivery port from the distal fluid delivery port that is not acoustically isolated to the vascular occlusion of about 1% of original concentration wherein the initial microbubble concentration in microbubble-therapeutic compound concentration is diluted to less than or equal to approximately 1% by volume, and the final concentration at the point of delivery to the vascular occlusion is further reduced to 0.01% of the initial microbubble concentration after passing the not acoustically isolated distal tip; and

delivering ultrasonic energy from the ultrasound assembly to the vascular occlusion concurrent to delivering the microbubble-therapeutic compound.

7. The method of claim 6, further comprising diluting the microbubble-therapeutic compound prior to delivering the microbubble-therapeutic compound, wherein the microbubble-therapeutic compound has an original microbubble concentration prior to the diluting, and the initial microbubble concentration is approximately 1% of the original microbubble concentration by volume.

8. The method of claim 6, wherein the microbubble-therapeutic compound comprises biological- or synthetic-shelled microbubbles.

9. The method of claim 8, wherein the lipid-shelled microbubbles are less than or equal to approximately 10 micrometers in diameter.

10. The method of claim 6, wherein the microbubble-therapeutic compound and/or ultrasonic energy are delivered continuously and concurrently.

11. The method of claim 6, wherein the ultrasonic energy has a peak rarefaction acoustic pressure less or equal to approximately 5.0 MPa.